Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Otrzymanie zabiegu terapią genową zamtocabtagene w badaniu klinicznym sponsorowanym przez Miltenyi Biomedicine w Ameryce Północnej
- •Dalsze uczestnictwo w badaniu i brak wycofania zgody
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 5, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (11)
Banner MD Anderson Cancer Center
Gilbert, United States
Stanford University
Stanford, United States
Yale University
New Haven, United States
Robert H Lurie Cancer Center
Chicago, United States
University of Kansas Cancer Center
Westwood, United States
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Baltimore, United States
Dana Farber Cancer Institute
Boston, United States
Duke University Medical Center - Division of Hematologic Malignancies
Durham, United States
Oregon Health and Science University Knight Cancer Institute
Portland, United States
UT Southwestern Medical Center
Dallas, United States
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, United States
Trial contact
Sadie Swift
Paris Jamiel
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/6/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.